CompletedPhase 1NCT00338026
A Phase I Study of ECO-4601 in Patients With Advanced Cancer
Studying Gonadal germ cell tumor
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Thallion Pharmaceuticals
- Principal Investigator
- Petr Kavan, MD, Ph.D.Sir Mortimer B. Davis - Jewish General Hospital
- Intervention
- ECO-4601(drug)
- Enrollment
- 26 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2006 – 2007
Study locations (2)
- Hôpital Charles LeMoyne, Greenfield Park, Quebec, Canada
- Sir Mortimer B. Davis Jewish General Hospital, Montreal, Quebec, Canada
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00338026 on ClinicalTrials.govOther trials for Gonadal germ cell tumor
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07318051Sample Collection for Ongoing Research and Product Evaluation StudyNatera, Inc.
- RECRUITINGNCT05645510LIVInG With chrONic Cancer TrEatments (LONGEVITI) StudyUniversity of Alberta
- RECRUITINGNANCT05142982Radiotherapy vs Observation for Post Chemotherapy Residual Mass in Advanced SeminomaTata Memorial Centre
- RECRUITINGNANCT05053230A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With CancerMemorial Sloan Kettering Cancer Center
- RECRUITINGPHASE1, PHASE2NCT04752826BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)BioInvent International AB
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT04205227ENB003 Plus Pembrolizumab Phase 1b/2a in Solid TumorsENB Therapeutics, Inc
- ACTIVE NOT RECRUITINGPHASE1NCT03872947A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid TumorsToray Industries, Inc
- RECRUITINGNANCT03787056Predictive Value of Progastrin Titer at Diagnosis and of Progastrin Kinetics During Treatment in Cancer PatientsHospices Civils de Lyon